Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 1492 | 24.37 |
09:34 ET | 726 | 24.37 |
09:36 ET | 300 | 24.55 |
09:38 ET | 200 | 24.5 |
09:41 ET | 176 | 24.63 |
09:43 ET | 100 | 24.585 |
09:45 ET | 1000 | 24.5148 |
09:48 ET | 1287 | 24.46 |
09:52 ET | 1455 | 24.4 |
09:54 ET | 700 | 24.475 |
09:56 ET | 100 | 24.45 |
09:59 ET | 100 | 24.41 |
10:01 ET | 200 | 24.5 |
10:03 ET | 300 | 24.57 |
10:06 ET | 3332 | 24.65 |
10:08 ET | 959 | 24.77 |
10:10 ET | 200 | 24.82 |
10:14 ET | 100 | 24.865 |
10:15 ET | 1103 | 24.73 |
10:17 ET | 500 | 24.645 |
10:21 ET | 400 | 24.625 |
10:24 ET | 550 | 24.49 |
10:28 ET | 100 | 24.41 |
10:32 ET | 100 | 24.505 |
10:33 ET | 149 | 24.468 |
10:42 ET | 100 | 24.465 |
10:44 ET | 200 | 24.37 |
10:46 ET | 200 | 24.4 |
10:48 ET | 1587 | 24.45 |
10:50 ET | 600 | 24.4 |
10:51 ET | 200 | 24.41 |
10:53 ET | 100 | 24.42 |
10:57 ET | 100 | 24.485 |
11:00 ET | 300 | 24.41 |
11:02 ET | 700 | 24.33 |
11:13 ET | 500 | 24.37 |
11:15 ET | 200 | 24.41 |
11:18 ET | 200 | 24.46 |
11:20 ET | 100 | 24.46 |
11:24 ET | 100 | 24.48 |
11:33 ET | 200 | 24.52 |
11:38 ET | 100 | 24.51 |
11:42 ET | 100 | 24.5 |
11:45 ET | 100 | 24.52 |
11:47 ET | 413 | 24.56 |
11:54 ET | 300 | 24.58 |
11:56 ET | 107 | 24.65 |
12:02 ET | 300 | 24.58 |
12:03 ET | 100 | 24.565 |
12:09 ET | 160 | 24.5355 |
12:16 ET | 100 | 24.58 |
12:18 ET | 100 | 24.615 |
12:21 ET | 6629 | 24.67 |
12:23 ET | 1079 | 24.565 |
12:25 ET | 899 | 24.51 |
12:27 ET | 100 | 24.52 |
12:30 ET | 300 | 24.515 |
12:32 ET | 201 | 24.5 |
12:36 ET | 506 | 24.51 |
12:38 ET | 600 | 24.36 |
12:39 ET | 446 | 24.45 |
12:43 ET | 300 | 24.41 |
12:48 ET | 100 | 24.44 |
12:50 ET | 500 | 24.4 |
12:52 ET | 900 | 24.39 |
12:56 ET | 535 | 24.23 |
12:57 ET | 500 | 24.37 |
01:12 ET | 100 | 24.37 |
01:19 ET | 200 | 24.33 |
01:21 ET | 200 | 24.37 |
01:28 ET | 100 | 24.325 |
01:30 ET | 400 | 24.32 |
01:33 ET | 100 | 24.23 |
01:35 ET | 300 | 24.295 |
01:39 ET | 600 | 24.24 |
01:42 ET | 100 | 24.2 |
01:44 ET | 200 | 24.22 |
01:46 ET | 100 | 24.215 |
01:48 ET | 800 | 24.24 |
01:50 ET | 100 | 24.24 |
01:51 ET | 225 | 24.21 |
01:55 ET | 100 | 24.215 |
02:04 ET | 100 | 24.18 |
02:08 ET | 200 | 24.21 |
02:09 ET | 500 | 24.26 |
02:11 ET | 100 | 24.22 |
02:15 ET | 100 | 24.28 |
02:18 ET | 103 | 24.32 |
02:20 ET | 100 | 24.24 |
02:29 ET | 200 | 24.35 |
02:31 ET | 500 | 24.27 |
02:38 ET | 261 | 24.24 |
02:44 ET | 100 | 24.3 |
02:47 ET | 600 | 24.15 |
02:49 ET | 400 | 24.17 |
02:58 ET | 200 | 24.16 |
03:02 ET | 2125 | 24.085 |
03:03 ET | 800 | 24.145 |
03:05 ET | 300 | 24.18 |
03:12 ET | 200 | 24.12 |
03:14 ET | 140 | 24.09 |
03:18 ET | 100 | 24.125 |
03:20 ET | 500 | 24.205 |
03:21 ET | 100 | 24.225 |
03:23 ET | 419 | 24.25 |
03:27 ET | 850 | 24.15 |
03:30 ET | 300 | 24.2 |
03:32 ET | 100 | 24.24 |
03:36 ET | 1017 | 24.22 |
03:38 ET | 200 | 24.23 |
03:39 ET | 100 | 24.2 |
03:41 ET | 200 | 24.2 |
03:43 ET | 400 | 24.18 |
03:45 ET | 200 | 24.195 |
03:48 ET | 200 | 24.15 |
03:50 ET | 917 | 24.175 |
03:52 ET | 1988 | 24.245 |
03:54 ET | 3421 | 24.27 |
03:56 ET | 1000 | 24.29 |
03:57 ET | 1304 | 24.25 |
03:59 ET | 29423 | 24.29 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.7B | -135.8x | --- |
CareDx Inc | 1.6B | -10.2x | --- |
Maravai LifeSciences Holdings Inc | 2.0B | -7.7x | --- |
MannKind Corp | 1.7B | 179.0x | --- |
Dynavax Technologies Corp | 1.5B | 110.7x | --- |
BioCryst Pharmaceuticals Inc | 1.5B | -10.2x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
---|---|
Revenue (TTM) | $338.9M |
Shares Outstanding | 71.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.34 |
EPS | $-0.18 |
Book Value | $6.23 |
P/E Ratio | -135.8x |
Price/Sales (TTM) | 5.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.